221 related articles for article (PubMed ID: 25157527)
1. Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease.
Marshall JK; Otley AR; Afif W; Bernstein CN; Hookey L; Leontiadis G; Panaccione R; Bressler B;
Can J Gastroenterol Hepatol; 2014; 28(7):371-2. PubMed ID: 25157527
[No Abstract] [Full Text] [Related]
2. Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy.
Rashidi A; Lee ME; Fisher SI
Int J Hematol; 2012 May; 95(5):592-4. PubMed ID: 22527855
[No Abstract] [Full Text] [Related]
3. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists.
Wallace TM; Veldhuyzen van Zanten SJ
Can J Gastroenterol; 2001 Jan; 15(1):21-8. PubMed ID: 11173323
[TBL] [Abstract][Full Text] [Related]
4. Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis.
Brinkert F; Arrenberg P; Krech T; Grabhorn E; Lohse A; Schramm C
Pediatrics; 2016 Sep; 138(3):. PubMed ID: 27516526
[TBL] [Abstract][Full Text] [Related]
5. Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.
Bašić Kinda S; Duraković N; Dotlić S; Serventi Seiwerth R; Davidović Mrsić S; Dubravčić K; Aurer I
Leuk Lymphoma; 2013 Jun; 54(6):1334-5. PubMed ID: 23083012
[No Abstract] [Full Text] [Related]
6. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Moran G; Dillon J; Green J
Inflamm Bowel Dis; 2009 Sep; 15(9):1281-2. PubMed ID: 19067412
[No Abstract] [Full Text] [Related]
7. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
Su CG; Stein RB; Lewis JD; Lichtenstein GR
Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
[TBL] [Abstract][Full Text] [Related]
8. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease.
Marion JF
Inflamm Bowel Dis; 1998 May; 4(2):116-7. PubMed ID: 9687219
[No Abstract] [Full Text] [Related]
10. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
11. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
12. Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases?
Poupeney S; Dray X; Reignier S; Vahedi K; Alhenc M; Belluci S; Marteau P
Inflamm Bowel Dis; 2008 Jul; 14(7):1024-5. PubMed ID: 18286642
[No Abstract] [Full Text] [Related]
13. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh JR; Oliva-Hemker M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
[No Abstract] [Full Text] [Related]
14. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
15. Safety of thiopurines in the treatment of inflammatory bowel disease.
de Jong DJ; Derijks LJ; Naber AH; Hooymans PM; Mulder CJ
Scand J Gastroenterol Suppl; 2003; (239):69-72. PubMed ID: 14743886
[TBL] [Abstract][Full Text] [Related]
16. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
17. Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients.
Fortes FML; Rocha R; Santana GO
World J Gastroenterol; 2023 Mar; 29(9):1536-1538. PubMed ID: 36998430
[TBL] [Abstract][Full Text] [Related]
18. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
19. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
Mackey AC; Green L; Leptak C; Avigan M
J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):386-8. PubMed ID: 19274799
[No Abstract] [Full Text] [Related]
20. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality.
Kotlyar DS; Blonski W; Diamond RH; Wasik M; Lichtenstein GR
Am J Gastroenterol; 2010 Oct; 105(10):2299-301. PubMed ID: 20927075
[No Abstract] [Full Text] [Related]
[Next] [New Search]